Sunday 20 November 2011

The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix

The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix.


Higher doses of the blood-thinner Plavix were no better at preventing nerve attacks, blood clots or destruction than the pennant soften quantity in patients who had received artery-opening stents, original scrutiny shows. The higher amount - double-dealing the usual amount - was tested in patients with "high platelet reactivity," message they failed to rejoin to the drug at lower doses diax od medicine. Plavix (clopidogrel) helps obstruct clots from forming in patients who have indecent platelet reactivity and who have had stents inserted to stay open blocked arteries.



But the uncharted study "doesn't support" physicians using the higher, 150-milligram dosage of Plavix after stenting, according to inspect lead author Dr Matthew Price, who presented the findings Tuesday at the annual convention of the American Heart Association in Chicago. So, the con leaves an distinguished question unanswered: How to explore heart patients who don't come back well to Plavix? "It remains in the balance to some extent," said Dr Abhiram Prasad, an interventional cardiologist with the Mayo Clinic in Rochester, Minn Provillus mumbai. "It's an substantial studio to have done but the clue issues are that a significant proportion of the patients remained with lofty platelet reactivity even after being on the higher dose".



Previous, smaller studies had indicated that Plavix might have more of an impression if the dispense was doubled. "Platelet reactivity varies widely," illustrious Price, director of the Cardiac Catheterization Laboratory at the Scripps Clinic in La Jolla, Calif. He explained that numerous studies have shown that a on a trip reactivity supine is associated with poorer outcomes after angioplasty and/or stenting skin cancer buy medicine. But until now, a bury originate in the measure of Plavix "has not been tested in a overwhelmingly randomized clinical trial," he said.